Table 3 Clinical studies registered in Clinicaltrials.gov using diet or dietary supplements/changes for hematologic and oncologic patients
From: Intestinal barrier functions in hematologic and oncologic diseases
NCT# | Study | Primary outcome measurements | Number of patients (n) |
|---|---|---|---|
04700527 | LCCC2032: The effects of short chain tatty acid supplementation on the quality of life and treatment-related toxicities in subjects receiving abdominopelvic radiotherapy: A randomized controlled study | The rate and severity of patient reported and physician determined toxicities between subjects who receive therapeutic SCFA and those who receive placebo | 122 |
05113485 | A fiber-diverse, anti-inflammatory diet and aerobic exercise reduce risk of breast cancer recurrence | High-sensitivity C-Reactive Protein (CRP) | 30 |
04538482 | Determining the structural-and functional-level effects of diet-specific interventions on the gut-microbiota of a diverse sample of southern United States adults | 1) Mean change in alpha diversity of intestinal microbiome; 2). Changes in bile acids; 3) Changes in inflammatory marker IL-6 | 112 |
05195970 | Microbiota, metabolites and colon neoplasia | 1) Bacterial composition and taxonomy changes in the fecal microbiome; 2) Bacterial diversity changes and strain-level variations in the fecal microbiome; 3) Bacterial gene expression profile changes in the fecal microbiome; 4) Urolithin levels in urine; 5) Association of urolithin levels with presence (and type) of colonic lesions; 6) Correlation of urolithin levels with fecal microbiome composition; 7) Correlation of colonic lesion gene expression with urolithin production | 200 |
02446431 | Metronomic therapy for pediatric patients with solid tumors at high risk of recurrence: A multi-institutional study | 1) 5Â year event free survival; 2) Number of participants with adverse events as a measure of safety and tolerability | 20 |
05039060 | A modified microbiota-accessible carbohydrates (MAC) diet and change of gut microbiota in patients with colorectal cancer after surgery: A prospective, open-label, cross-over, single center study | The change of gut microbiota diversity | 40 |
05708326 | Does timing matter? A case crossover study of intermittent fasting in patients with CLL/SLL at BC Cancer- Victoria | 1) Change in lymphocyte count; 2) Change in inflammation; 3) Change in metabolomic profiles; 4) Change in autophagy status; 5) Changes in immune cell gene expression profiles | 8 |